Abstract | INTRODUCTION: METHODS: An instrumental variable meta-analysis was performed to infer the effect of change in positron emission tomography (PET)-measured Aβ standardized uptake value ratio (SUVR) on cognitive and functional decline. RESULTS: Pooling data from 16 randomized trials demonstrates that each 0.1-unit decrease in PET Aβ SUVR is associated with a reduction (95% confidence interval) by 0.09 (0.034-0.15), 0.33 (0.12-0.55), and 0.13 (0.017-0.24) point in the average change of the Clinical Dementia Rating-Sum of Boxes, the Alzheimer's Disease Assessment Scale-Cognitive Subscale, and the Mini-Mental State Examination, respectively. DISCUSSION: This meta-analysis provides statistically significant evidence of a likely causal relationship between a reduction in Aβ plaque and a reduction in cognitive and functional decline in patients with AD. HIGHLIGHTS: A widely cited meta-analysis article concluded amyloid beta reduction does not substantially improve cognition. We identified data inconsistencies in the initial publication and found new trial data. We repeated the meta-analysis after correcting data inconsistencies and adding new trial data. Updated results suggested statistically significant clinical benefit of amyloid beta reduction. Amyloid beta is a viable biological target for the treatment and prevention of AD.
|
Authors | Menglan Pang, Ling Zhu, Audrey Gabelle, Arie R Gafson, Robert W Platt, James E Galvin, Pierre Krolak-Salmon, Ivana Rubino, Carl de Moor, Shibeshih Belachew, Changyu Shen |
Journal | Alzheimer's & dementia : the journal of the Alzheimer's Association
(Alzheimers Dement)
Vol. 19
Issue 4
Pg. 1292-1299
(04 2023)
ISSN: 1552-5279 [Electronic] United States |
PMID | 36043526
(Publication Type: Meta-Analysis, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. |
Chemical References |
- Amyloid beta-Peptides
- Amyloid
|
Topics |
- Humans
- Alzheimer Disease
(diagnostic imaging, psychology)
- Amyloid beta-Peptides
(metabolism)
- Brain
(diagnostic imaging, metabolism)
- Cognitive Dysfunction
(diagnostic imaging)
- Positron-Emission Tomography
(methods)
- Amyloid
- Cognition
|